CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05319860
NCT05319860Phase 2Completed
CompareCT.gov

Effects of Aromatherapy on Chemotherapy-Induced Nausea and Vomiting: A Control Trial

University of Miami·interventional·Posted Apr 8, 2022·Updated Apr 17, 2025

In Brief

A Phase 2 clinical trial evaluating Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV) and Aromatherapy Care for Chemotherapy-induced Nausea and Vomiting. Completed, enrolled 100 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the use of aromatherapy to reduce nausea, vomiting, and the use of anti-emetic in cancer survivors undergoing moderate to highly emetogenic chemotherapy regimens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapy-induced Nausea and Vomiting
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedApr 8, 2022
Enrollment StartAug 1, 2022
Primary CompletionApr 15, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.2 years ago

Interventions

Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)drug

Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.

Aromatherapy Caredrug

An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.